entertainment -WSS

entertainment

author：fashion 2025-09-29 18:17:51 - browse：282

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Hilary expected to bring catastrophic, life

WSS

Ukraine taking heavy casualties 10 weeks into its counteroffensive

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Living with Hashimoto's and celiac disease, and med school, too

Medicare innovation center doesn’t save money, experts say

The Karikó problem: Lessons for funding basic research

Lung cancer is America's deadliest cancer. Yet so few get screened

focus

entertainment

focus

As demand for Covid shots wanes, Moderna seeks its next success

Congress extends some pandemic preparedness programs

The cancer drug shortage isn’t new — and neither are the solutions

New definition of a human embryo proposed amid rapid advances

Medical leaders decry Supreme Court decision on affirmative action

The Karikó problem: Lessons for funding basic research

Malaria cases in Florida and Texas: Here’s what you need to know

The stability of $0 premiums in Medicare Advantage

Virginia high school admissions case could be legal follow

With Roe v Wade overturned, abortion providers work to adapt

entertainment

What we owe ALS patients — and why one company fell short

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

The biotech scorecard for Q4: 16 stock

Congress extends some pandemic preparedness programs

The biotech scorecard for Q4: 16 stock

Lawsuit highlights wrinkle for disputes over surprise medical bills

explore

entertainment

focus

knowledge